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TSObjective: The aim of the study was to determine the impact of tumor-infiltrating lym-
phocytes on survival in patients with malignant pleural mesothelioma treated with
induction chemotherapy followed by extrapleural pneumonectomy.
Methods: We performed an immunohistochemical analysis of 32 extrapleural pneu-
monectomy specimens to assess the distribution of T-cell subtypes (CD31, CD41,
and CD81), regulatory subtypes (CD251 and FOXP31), and memory subtype
(CD45RO1) within the tumor.
Results: Patients with high levels of CD81 tumor-infiltrating lymphocytes demon-
strated better survival than those with low levels (3-year survival: 83% vs 28%;
P 5 .06). Moreover, high levels of CD81 tumor-infiltrating lymphocytes were asso-
ciated with a lower incidence of mediastinal node disease (P 5 .004) and longer
progression-free survival (P 5 .05). Higher levels of CD81 tumor-infiltrating lym-
phocytes were observed in patients treated with cisplatin and pemetrexed than in those
treated with cisplatin and vinorelbine (P 5 .02). Patients presenting high levels of
CD41 or CD251 tumor-infiltrating lymphocytes or low levels of CD45RO1 also
demonstrated a trend toward shorter survival. However, the presence of FOXP31
tumor-infiltrating lymphocytes did not affect survival. After multivariate adjustment,
high levels of CD81 tumor-infiltrating lymphocytes remained an independent prog-
nostic factor associated with delayed recurrence (hazard ratio 5 0.38; confidence
interval 5 0.09–0.87; P 5 .02) and better survival (hazard ratio 5 0.39; confidence
interval 5 0.09–0.89; P 5 .02).
Conclusion: The presence of high levels of CD81 tumor-infiltrating lymphocytes is
associated with better prognosis in patients undergoing extrapleural pneumonectomy
for malignant pleural mesothelioma. The stimulation of CD81 lymphocytes can be
a potential therapeutic strategy to improve outcome.
M
alignant pleural mesothelioma (MPM) is an aggressive tumor arising from
the pleura, with a poor prognosis and a median survival of 9 to 12 months
from diagnosis.1 The incidence of MPM is increasing worldwide because
of past exposure to asbestos in industrialized countries up to the 1970s. Multimodality
therapy with chemotherapy, surgery, and hemithoracic postoperative irradiation have
demonstrated some benefit in survival for highly selected patients,2–4 but the majority
of cases are noncurative. Therefore, some emerging modalities, such as immunother-
apy,5 intracavitary chemotherapy,6,7 and photodynamic therapy,8 have been tested to
offer hope for improvement in both palliation and survival.
Clinical studies conducted during the last decade demonstrated that MPM is
sensitive to immune-based therapies. Intrapleural administration of interleukin-
2,9,10 interferon alpha,11,12 and interferon gamma13 have had some impacts on tumor
regression and decreased pleural effusion when combined with chemotherapy. The
underlying pathophysiologic mechanism is complex and still largely unknown; how-
ever, the encouraging results of these immunomodulating approaches suggest that
MPM is potentially immunogenic.
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TSAbbreviations and Acronyms
EPP 5 extrapleural pneumonectomy
MPM 5 malignant pleural mesothelioma
TIL 5 tumor-infiltrating lymphocyte
TUNEL 5 deoxyuride-50-triphosphate biotin nick
end labeling
Recent evidence suggests that the tumor microenviron-
ment and the interaction among the tumor cells, immune
cells, stromal cells, and extracellular matrix are crucial in
tumor progression.14 In particular, tumor-infiltrating lympho-
cytes (TILs) have been recognized as principal effectors of
local antitumor immune response.15 Recent studies also
demonstrated the presence of regulatory lymphocytes in the
tumor microenvironment that possess various functions in
modulating local tumor immunity.16
The presence and role of TILs remain poorly defined in
MPM. In this study, we analyzed the impact of both cytotoxic
and regulatory phenotypes of TILs on survival in patients
with MPM. Immunostaining with T-cell subtypes (CD3,
CD4, CD8), regulatory subtypes (CD25, FOXP3), and mem-
ory subtype (CD45RO) were used to select the different
phenotypes within the tumors.
Materials and Methods
Patients and Specimens
Formalin-fixed, paraffin-embedded tissues were obtained from
32 patients who underwent induction chemotherapy followed by
extrapleural pneumonectomy (EPP) for MPM at the Toronto Gen-
eral Hospital between December of 1997 and July of 2005. All tis-
sues were collected under an institutional ethical board-approved
protocol. Histopathologic diagnosis was established by our institu-
tion’s pathologists. Pathologic and clinical findings were scored
according to the TNM staging system proposed by the Interna-
tional Mesothelioma Interest Group.17 The duration of progres-
sion-free survival was the time between the surgery and the first
recurrence. The recurrent disease was confirmed radiographically,
cyto/histologically, or both. Overall survival was defined as the in-
terval between the date of surgery and death, and all patients were
followed up every 3 to 6 months until either their death or October
31, 2006.
Histopathologic Analysis and Construction of
Tissue Arrays
All available histologic sections of tumor stained with hematoxylin-
eosin were assessed by an investigator (M.A.) and one of our institu-
tion’s pathologists (K.S.C.) for TILs. On the basis of this assessment,
paraffin-embedded samples corresponding to the hematoxylin-
eosin–stained slides were processed into tissue array blocks, which
consisted of 4 cores per case with a core diameter of 1.5 mm using
a tissue microarray instrument (Tissue Arrayer I, Beecher Instru-
ments Inc, Sun Prairie, Wis). Tissue array blocks were then cut
into 4-mmsections for hematoxylin-eosin and immunohistochemical
staining.824 The Journal of Thoracic and Cardiovascular Surgery c ApImmunohistochemistry Analysis
The antibodies used were as follows: anti-human CD3 (polyclonal;
Dako, Carpinteria, Calif), anti-human CD4 (clone BC/1F6; Abcam,
Cambridge, UK), anti-human CD8 (clone 4B11; Novocastra Labo-
ratories, Ltd. Newcastle upon Tyne, UK), anti-human CD45RO
(clone OPD4, Dako), anti-human CD25 (clone 4C9; Vector Labora-
tories, Burlingame, Calif), and anti-human FOXP3 (mAb-
cam22510; Abcam). Sections from the tissue array blocks were
deparaffinized in xylene, washed in phosphate-buffered saline (pH
7.4), and rehydrated through a graded ethanol series. For anti-human
CD3 antibody, the enzyme digestion method was applied with 1%
pepsin in 0.01 N HCl (pH 2.0) at 37C for 15 minutes. For anti-hu-
man CD8, CD25, CD45RO, and FOXP3 antibodies, deparaffinized
sections were immersed into 10 mmol/L of preheated citrate buffer
(pH 6.0), incubated at 95C for 20 minutes, and allowed to cool to
room temperature. For anti-human CD4 antibody, preheated Tris-
EDTA buffer (pH 9.0) was used for antigen retrieval at 95C for
20 minutes. Endogenous peroxidase and biotin activities were
blocked respectively using 3% hydrogen peroxide and an avidin/bi-
otin blocking kit (Vector Laboratories). After blocking for 15 min-
utes with 10% normal goat serum, sections were incubated
accordingly at room temperature for either 1 hour (anti-human
CD3, CD8, and CD45RO) or overnight (anti-human CD4, CD25,
and FOXP3) with each primary antibody. NovaRed solution (Vector
Laboratories) was applied for color development followed by coun-
terstaining with hematoxylin. Negative control slides omitting pri-
mary antibodies were included for all experiments.
Assessment of Tumor Cell Apoptosis
To analyze the interrelationship between the presence of TILs and
tumor-cell apoptosis, we performed terminal deoxyuride-50-tri-
phosphate biotin nick end labeling (TUNEL) on the tissue array
slides. The In Situ Cell Death Detection Kit (Roche, Nutley, NJ)
was used according to the manufacturer’s protocol. To distinguish
tumor cells from other types of cells, a double immunofluorescent
staining with antihuman mesothelin antibody (clone SPM143; Ab-
cam) was performed after TUNEL. Mesothelin is a maker for me-
sothelium-derived cells, including MPM.18 Slides were incubated
with antihuman mesothelin antibody at room temperature for 2
hours followed by conjugation with Alexa Fluor 488 (Invitrogen,
Carlsbad, Calif) as a secondary antibody. Nuclei were stained with
Hoechst 33258 (Sigma, St Louis, Mo). Only cells positive for both
TUNEL and antihuman mesothelin were considered as apoptotic
tumor cells.
Positive Cell Quantification
Antibody stained slides were digitally scanned using Aperio Scan-
Scope CS (Aperio Technologies, Vista, Calif), and the scanned im-
ages were analyzed with ImageScope (Aperio Technologies) for the
positive cell quantification. All 4 spots of each case were evaluated
for TILs, and a minimum of 4 independent areas (up to 6 areas) with
the most abundant immunohistochemically positive TILs were se-
lected at a size of 0.0625 mm2. Positive cells in the selected areas
for each antibody were counted independently by 2 investigators
(M.A. and Z.Y.) without knowledge of clinical information. The av-
erages of positive TILs for each antibody were used for statistical
analyses. For the apoptotic tumor-cell quantification, both TUNEL
and mesothelin-positive cells were counted for all 4 spots per caseril 2008
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ing analyses.
Statistical Analysis
Kaplan–Meier survival curves were used to estimate survivals on
the basis of the levels of positive TILs and were compared with
the log-rank test. Multivariate Cox proportional hazards models
were used to calculate adjusted hazard ratios. Covariates included
in the multivariate analyses were the level of CD81 T cells (high
vs low level), tumor stage (stage II vs stage III/IV), and cell type (ep-
ithelioid vs others). Cutoff values for the positive TIL counts to de-
fine subgroups were the 25th or 50th percentile, that is, the top 25th
or 50th percentile was defined as a high level and all others were de-
fined as low levels. Correlation between the numbers of positive
TILs and the patients’ clinicopathologic factors were tested with ei-
ther the t test or the Wilcoxon–Mann–Whitney test, depending on
the distribution of positive cell counts. The normality of the distribu-
tion of positive cell counts for each antibody was determined with
the Shapiro–Wilk test (the distribution of TIL counts was judged
as a normal distribution when the P value was more than .05). Ap-
optotic tumor cell counts were analyzed in association with TIL
counts and clinicopathologic factors. The chi-square test was used
when categoric variables were analyzed. All analyses were per-
formed with JMP 5.0 software (SAS Institute Inc, Cary, NC).
Results
Patient Characteristics
Patient characteristics are summarized in Table 1. There were
28 men and 4 women. The median age was 59 years (range,
21–74 years). Postoperative pathologic examination of the
lymph nodes revealed n0 in 13 patients, n1 in 5 patients,
n2 in 13 patients, and n3 in 1 patient. The median follow-
up period was 35 months (range, 9–63 months). All patients
received cisplatin-based induction chemotherapy followed
by EPP. Postoperative hemithoracic irradiation was per-
formed in 23 patients (72%) with a dose ranging from 30
TABLE 1. Demographic information for patients with











Cisplatin 1 vinorelbine 17
Cisplatin 1 pemetrexed 9
Cisplatin 1 gemcitabine 3




The average counts of positive TILs per area for each anti-
body were as follows: CD31 (average6 standard deviation;
232.16 114.1), CD41 (119.96 94.2), CD81 (73.16 40.2),
CD251 (17.5 6 12.6), FOXP31 (21.8 6 19.0), and
CD45RO1 (115.7 6 56.2). As shown in Figure 1, the cell
counts of CD31 and CD45RO1 TILs showed normal distri-
bution (Shapiro–Wilk test; P 5 .1 and .3), whereas CD41,
CD81, CD251, and FOXP31 TILs did not (P , .05). Rep-
resentative pictures of immunohistochemical staining of
TILs are shown in Figure 2.
Correlations between subtypes of TILs and lymph node
metastasis were analyzed. Only the presence of CD81 TILs
significantly affected lymph node metastasis (P 5 .004).
Eight of 18 patients who had n0 or n1 disease demonstrated
high levels of CD81 TILs, whereas all patients with medias-
tinal node disease (n2 and n3, n 5 14) showed low levels of
CD81 TILs (average 6 standard deviation; 84.6 6 47.9 vs
58.46 20.8). The tumor samples from patients who received
cisplatin/pemetrexed chemotherapy demonstrated higher
levels of CD81 TILs when compared with those from pa-
tients treated with cisplatin and vinorelbine (average6 stan-
dard deviation; 91.4 6 52.4 vs 53.4 6 28.6, P 5 .02).
Tumor Apoptosis and Tumor-infiltrating
Lymphocytes
Mesothelin was positive for all tumors in the current study
subjects (Figure 3). The median number of both TUNEL
and mesothelin double-positive cells (ie, apoptotic tumor
cells) was 11.4 (range, 0–85). Significantly higher numbers
of apoptotic tumor cells were observed in the tumors with
high levels of CD81 TILs compared with those with low
levels (P 5 .02). No correlations were observed between
the presence of apoptotic tumor cells and other types of
TILs. There was no significant difference in the numbers of
apoptotic tumor cells in the tumors treated with cisplatin
and pemetrexed when compared with those treated with
cisplatin and vinorelbine (P 5 .7).
Prognostic Significance of Tumor-infiltrating
Lymphocytes
We hypothesized that effector subtypes of TILs would affect
the prognosis favorably and that regulatory subtypes of TILs
would have a negative impact. To determine the relationships
between the levels of various subtypes of lymphocytes and
patient prognosis, we performed both univariate and multi-
variate analyses.
Overall estimated 3- and 5-year survivals were 35% and
28%, respectively. The median survival for all patients was
12.2 months. Tumor recurrence was found in 17 patientsracic and Cardiovascular Surgery c Volume 135, Number 4 825
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TILs.(53%) at either local (n 5 6) or distant (n 5 11) sites. There
were 3 postoperative deaths, and these were excluded from
the analyses to assess the correlation between survival and
the levels of TILs. CD31 (pan-T-cell marker) TILs were
not associated with either prolonged or shortened survival
(P 5 .8). There was a clear correlation between high levels
of CD81 TILs and overall survival (Figure 4, A), as well as
progression-free survival (Figure 4, B). High levels of helper
TILs (CD41) and regulatory/activated TILs (CD251) indi-
cated poor prognosis (3-year survival: 15% vs 53%; P 5
.08, and 17% vs 45%; P 5 .09, respectively; Figure 5, A
and B). No difference in survival according to the levels of
FOXP31 TILs was observed (P 5 .8; Figure 5, C). High
levels of CD45RO1 (memory T-cell marker) TILs adversely
affected survival, although the difference between the groups
did not reach statistical significance (P 5 .08; Figure 5, D).
After multivariate adjustments, the presence of CD81 TILs
remained a significant prognostic factor for both prolonged
progression-free survival (hazard ratio 5 0.38; 95% confi-
dence interval 5 0.09–0.87; P 5 .02) and overall survival
(hazard ratio 5 0.39; 95% confidence interval 5 0.09–
0.89; P 5 .02) (Table 2).
Discussion
Accumulating evidence suggests that TILs play an important
role in mediating local tumor immunity. It has been demon-
strated that CD81 cytotoxic T cells play crucial roles in
antigen-specific tumor cell killing, whereas CD41CD251
regulatory T cells are key mediators of suppressing tumor
immunity.19 In MPM, Leigh and Webster20 first reported
the significance of lymphocytic infiltration in survival, al-
though phenotypic analyses of lymphocytes were not per-
formed. In their study, 33 of the 35 patients who died
within 9 months of their initial presentation showed insignif-826 The Journal of Thoracic and Cardiovascular Surgery c Apicant or absent lymphoid reaction on pretreatment biopsy
specimens. In contrast, 10 of the 15 patients who survived
18 months or more demonstrated significant lymphocytic in-
filtration on the biopsy specimens. In the current study, we
clearly observed that the presence of CD81 TILs is a favor-
able sign of good clinical outcome after induction chemother-
apy followed by EPP. The favorable prognostic impact of
CD81 TILs was confirmed by multivariate analysis with
other relevant clinicopathologic factors, including cell type
and tumor stage. In addition, we found that high levels of
CD81 TILs correlated with a low incidence of mediastinal
lymph node metastases. This could be an important observa-
tion to help select candidates for EPP considering that media-
stinoscopy and positron emission tomography have a low
accuracy to detect nodal metastasis before EPP.21,22
Chemotherapy may alter the tumor microenvironment and
increase the susceptibility to an antitumor immune response.
It has been shown that chemotherapy-induced apoptotic
tumor cells can potentially augment antitumor cytotoxic
T-cell responses.23 In our study, we observed that the pres-
ence of TUNEL-positive apoptotic tumor cells correlated
with high levels of CD81 TILs. In addition, a significant
correlation between induction cisplatin/pemetrexed chemo-
therapy and high levels of CD81 TILs was also observed in
our study, suggesting that this drug combination may induce
greater antitumor immune responses. Because cisplatin/pe-
metrexed chemotherapy is the only regimen that has been
shown to have a significant impact on survival in a random-
ized clinical trial for MPM,24 the mechanism by which the
chemotherapy-induced apoptosis augments CD81 T-cell–
mediated antitumor responses is of great interest.
In our study, we found that CD251 TILs were negatively
correlated with prognosis; however, this was not statistically
significant. Regulatory T cells, which are characterized byril 2008
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3400.-Figure 3. An apoptotic tumor cell (bot
tom right, arrow) was demonstrated as
double positive for TUNEL in a nucleus
(purple) and mesothelin in cytoplasm
(green). Nuclei were stained with
Hoechst 33258 (blue). Magnification
3400.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 4 827
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TSFigure 4. Survival analysis for patients
who underwent EPP after induction
chemotherapy according to levels of
CD81 TILs. A, Overall survival. B, Pro-
gression-free survival.the expression of both CD4 and CD25, can induce a ‘‘tumor
tolerance’’ state by suppressing effector or helper T cells.19
Regulatory T cells can also impair the function of dendritic
cells that are indispensable in antigen presentations to both
CD41 helper and CD81 cytotoxic T cells. On the contrary,
FOXP3, a specific marker for naturally occurring regulatory
T cells and a crucial transcription factor that mediates the reg-
ulatory T-cell development and function,25 did not have any
impact on the posttreatment prognosis of MPM. This may be
partly because the numbers of lymphocytes positive for
FOXP3 were small in our study. Although there are a few
studies exploring the role of regulatory T cells in MPM, it
is often not well defined because of their small sample
size.26,27 Hegmans and colleagues26 demonstrated a massive
influx of CD41CD251FOXP31 T cells in 4 biopsy speci-
mens of MPM, and DeLong and colleagues27 reported fewer
CD41CD251 T cells in pleural effusions from 7 patients with
MPM when compared with those from patients with non–
small cell lung cancer or breast cancer. Extended research in-
cluding functional studies of TILs is required to determine
the role of regulatory T cells in MPM, especially their inter-
action with CD81 cytotoxic T cells.
Conclusions
Our results demonstrate that the presence of CD81TILs is as-
sociatedwith favorable prognosis inMPM treatedwith induc-
tion chemotherapy followed by EPP. Further studies are
required to investigate the functional properties of effector,
Figure 5. Survival analyses with sub-
types of tumor-infiltrating lymphocytes.
Overall survival according to levels of:
A, CD41 TILs; B, CD251 TILs; C, FOXP31
TILs; and D, CD45RO1 TILs.828 The Journal of Thoracic and Cardiovascular Surgery c April 2008
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nale for developing immunomodulating approaches to aug-
ment CD81 cytotoxic T cells for both better local control
and prolonged survival in MPM. In particular, MPM is natu-
rally resistant to chemotherapy; thus, more effective treatment
requires combined approaches with chemotherapy and im-
mune-based therapies that may introduce synergistic antitu-
mor effects. Further studies should evaluate the potential
benefits of chemotherapy on antitumor immune responses
to incorporate immune-based approaches into the current
treatment strategy.
We thank Kelvin So for expert assistance with the immunohisto-
chemical stainings.
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